SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION

• Main Authors: GOURVEST, JEAN-FRANCOIS, GADEK, THOMAS, KNOLLE, JOCHEN, RUXER, JEAN-MARIE, PEYMAN, ANUSCHIRWAN
• Format: Patent
• Language: English
• Published: 03.09.2004
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Ovaj pronalazak se odnosi na jedinjenja formule (I) u kojoj B, D, E, G, X, Y, Z, R1, R2 i s imaju značenja koja su navedena u patentnim zahtevima, njihove fiziološki prihvatljive soli i njihove prolekove. Jedinjenja formule (I) su korisna farmakološki aktivna jedinjenja. Ona su antagonisti vitronektin receptora i inhibitori adhezije ćelije i pogodni su za terapiju i profilaksu bolesti koje su zasnovane na interakciji izmedju vitronektin receptora i njihovih liganda u procesima ćelija-ćelija ili ćelija-matriks interakcije ili koje mogu svojim uticajem na takve interakcije da dovedu do prevencije, poboljšanja ili izlečenja. Na primer, mogu se davati za inhibiciju resorpcije kostiju do koje dovode osteoklasti i na taj način za lečenje i prevenciju osteoporoze ili za inhibiciju neželjenih angiogeneza ili proliferaciju ćelija krvnih sudova glatke muskulature. Pronalazak se dalje odnosi na postupak za dobijanje jedinjenja formule (I), njihovu upotrebu posebno kao aktivnih sastojaka u lekovima i farmaceutskim kompozicijama koje ih uključuju. The present invention relates to compounds of the formula I, in which B, D, E, G, X, Y, Z, R , R and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.